TRUSTSWAP
24.8.2021 22:41:13 CEST | Business Wire | Press release
Jani Leinonen, the renowned Finnish artist, will offer a 3 day NFT auction of his one-of-one animated artwork titled ‘Things You Own’, on Swappable , until Friday, August 27th at 10am PST. Swappable is a new interface for non-fungible tokens (NFTs) powered by TrustSwap .
Leinonen will be participating in an AMA Ask-Me-Anything event, offering the opportunity for the community to ask him questions.
Leinonen’s first NFT is supported by Stalla Madulain , the renowned Swiss art gallery dating back to 1488 and one of his most ardent supporters. As well as Switzerland-based international fine art logistics and infrastructure provider Haas & Company AG , a reputed partner of art collectors, galleries, museums, and art fairs worldwide which provides custody services for tokenized physical assets.
Swappable, powered by TrustSwap , will create a creative place for artists to sell their artworks and for users to find and collect artworks and digital collectibles. Jeff Kirdeikis, CEO of TrustSwap, mentions: “We are extremely excited to be working with such a renowned artist, we’ve created a platform that reduces the entrance barrier to the NFT space to support creators like Jani Leinonen.”
Leinonen is known for his provocative, yet playful works, criticizing capitalism and consumerism. In 2016, Leinonen was awarded the Finland Prize by the Ministry of Education and Culture, which is given in recognition of a significant career in arts. His work can be found in museums, and in private and public collections on every continent. He is currently exhibiting in Serlachius Museum with the street artist Banksy, and Salo Art Museum. The Five-star hotel Dolder Grand in Zurich has 12 of Leinonen’s works on permanent display. You can find out more about Leinonen on his website .
Jani Leinonen, on his NFT artwork ‘Things you own’: “Have we become more consumers than citizens? Our values, our political views, our emotions, traumas, and our dreams, are revealed by this sacred shopping cart. When we take a look at this portrait of us, how much do we recognize as our own? Will there truly be a new better world displacing the established and old, or will we forever be owned by the things we own?”
The team behind Swappable boasts that the Jani Leinonen collaboration is just the beginning, with many interesting collaborations to be revealed soon.
Swappable is the latest offering from TrustSwap
TrustSwap is a blockchain venture that offers smart contact services and innovative solutions for decentralized finance (DeFi) and commerce to help the crypto community transact with integrity, and accountability. TrustSwap solves problems in the DeFi space connected to tracking and buying crypto with ‘The Crypto App’, split payments, subscriptions, escrow, minting, token locks, and fundraising. TrustSwap is building foundational layers in the rapidly-emerging decentralized finance and commerce landscape with services like The Crypto App, SmartLocks, Mint, Launchpad, and Swappable’s NFT interface. Visit www.trustswap.org for information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005826/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom